Minerva Neurosciences Inc (NERV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.43-5.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NERV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
NERV — earnings miss
Dated 2026-08-07
of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.
Why it matters: High R&D expenses indicate ongoing commitment to the C19 trial, which is key for future growth.
Supportive ifR&D costs will stay above $7 million in the next quarters as the C19 trial goes on.
Worry ifR&D costs fall below $5 million, showing less focus on the C19 trial.
Why it matters: Finishing patient enrollment is key for the Phase 3 trial and its success.
Supportive ifEnrollment of all 380 patients in the Phase 3 trial is completed on or ahead of schedule.
Worry ifEnrollment is delayed much longer than expected.
Why it matters: If healthcare revenue growth speeds up, it could improve sentiment for NERV.
Supportive ifHealthcare sector revenue growth shows a return to near 10% growth rates.
Worry ifHealthcare sector revenue growth keeps slowing down below current rates.
Why it matters: Enrollment progress is key for the trial's success. Delays could signal deeper issues.
Supportive ifManagement says patient enrollment for the Phase 3 trial has started as planned.
Worry ifEnrollment is delayed beyond the expected timeline. There is no clear reason for this.
Why it matters: Comparing NERV to stronger companies like LLY and ABBV shows its market position.
Worry ifNERV's score improves a lot, getting closer to its peers.
Less concerning ifNERV's score drops or stays below 9.0, showing weaker performance.
Why it matters: Results will show if roluperidone helps with negative symptoms of schizophrenia. This is key for the drug's future.
Supportive ifResults from the C19 trial show good effects for roluperidone at 12 weeks.
Worry ifResults from the C19 trial show no major effect of roluperidone.
Why it matters: Continued losses could signal ongoing issues in managing costs and cash burn.
Worry ifOperating losses worsen from negative $16.7 million in Q1 to worse in Q2.
Less concerning ifOperating losses get better or stay the same. This shows improved cost management.
Why it matters: The leadership change may affect the direction and progress of the C19 trial.
Watch forJim O'Connor uses strategies that help the C19 trial and support company goals.
Also watch forLeadership transition leads to delays or setbacks in the C19 trial execution.
Why it matters: Enrollment progress shows the trial is moving forward and may release data on time. Delays could mean problems.
Supportive ifEnrollment hits or goes over 380 patients in the C19 trial on schedule.
Worry ifEnrollment is far behind the target of 380 patients.
Why it matters: Changes in leadership can change the company's direction and affect trial results.
Watch forNew leaders show a clear plan and keep trial timelines and quality.
Also watch forLeadership changes cause delays or confusion in running the trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$270 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $947 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,143 loss on $10,000 · 51.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.